Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132434) titled 'Effect of Yangxin Dingji Capsules Combined with Dronedarone on the Prognosis of Patients Undergoing Radiofrequency Catheter Ablation for Atrial Fibrillation' on Sept. 14.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The second hospital of hebei medical university
Condition:
Paroxysmal Atrial Fibrillation
Intervention:
Trial group:For 3 months after the procedure, the patients received oral rivaroxaban tablets, dronedarone tablets, and Yangxin Dingji capsules (rivaroxaban: 15 mg once daily
dronedarone: 400 mg once daily
Yangxin Dingji capsules: 0.5 g per capsule, 6 capsules per ...